SAB Biotherapeutics

SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing human immunoglobulin therapies from its engineered platform, led by disease-modifying SAB-142 for Stage 3 Type 1 Diabetes. The company develops multi-specific, high-potency human immunoglobulin G therapies for immune and autoimmune disorders through proprietary technology that uses advanced genetic engineering and antibody science to generate novel therapeutic candidates from the human immune response without human donors or convalescent plasma.

SAB Biotherapeutics' work addresses the underlying cause of Type 1 Diabetes—an over-reactive immune response attacking insulin-producing beta cells in the pancreas—rather than symptom management with insulin. SAB-142 is its lead product candidate, a disease-modifying therapy for autoimmune Type 1 Diabetes that aims to delay onset and prevent progression in Stage 3 Type 1 Diabetes patients.